Skip to Main content Skip to Navigation
Journal articles

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV

Abstract : Since the beginning of the COVID-19 pandemic, large in silico screening studies and numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV-2. In the context of health emergency, drug repurposing represents the most relevant strategy because of the reduced time for approval by international medicines agencies, the low cost of development and the well-known toxicity profile of such drugs. Herein, we aim to review drugs with in vitro antiviral activity against SARS-CoV-2, combined with molecular docking data and results from preliminary clinical studies. Finally, when considering all these previous findings, as well as the possibility of oral administration, 11 molecules consisting of nelfinavir, favipiravir, azithromycin, clofoctol, clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and hydroxychloroquine, show an interesting antiviral activity that could be exploited as possible drug candidates for COVID-19 treatment.
Complete list of metadata
Contributor : Isabelle COMBE Connect in order to contact the contributor
Submitted on : Monday, May 9, 2022 - 4:49:12 PM
Last modification on : Tuesday, May 10, 2022 - 3:47:04 AM

Links full text




Sarah Aherfi, Bruno Pradines, Christian Devaux, Stéphane Honore, Philippe Colson, et al.. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiology, Future Medicine, 2021, 16 (17), pp.1341-1370. ⟨10.2217/fmb-2021-0019⟩. ⟨hal-03662935⟩



Record views